746P Phase III MIRASOL trial: Updated overall survival results of mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in patients (pts) with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression

• DOI: 10.1016/j.annonc.2024.08.807
• Publication Date: 2024-09-17T20:11:22Z
• Authors: L. Gardner Coffman; B. You; E.P. Hamilton; Y. Garcia Garcia; K.N. Moore; D. Sonnenburg; G. Scambia; S. Derio; J. Thomes Pepin; D. Klasa-Mazurkie...; J. Tromp; S. Breuer; S. Weroha; O. Sukhina; Y. Wang; J.J. Stec; T. Van Gorp